Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- Status
- RECRUITING
- Phase
- PHASE2
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
- Status
- RECRUITING
- Phase
- PHASE2
A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Status
- TERMINATED
- Phase
- PHASE1
Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Improve Checkpoint-blockade Response in Advanced Urothelial Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
- Status
- RECRUITING
- Phase
- PHASE2
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
- Status
- TERMINATED
- Phase
- PHASE2
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)
- Status
- COMPLETED
- Phase
- PHASE3